Decoy Therapeutics
DCOY
1 hedge funds and large institutions have $1.08M invested in Decoy Therapeutics in 2019 Q2 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, reducing their positions, and closing their positions.
8% more capital invested
Capital invested by funds: $1M → $1.08M (+$83K)
0% more funds holding
Funds holding: 1 → 1 (0)
0% more ownership
Funds ownership: 0% → 0% (0%)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$144K |
| 2 |
VF
Virtu Financial
New York
|
-$52K |
| 3 |
WS
Wedbush Securities
Los Angeles,
California
|
-$39K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$18K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$17K |
DCOY Hedge Fund Activity: Q2 2019 in Review
1 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q2 2019, worth a combined $1.08M — up 8.3% from $1M a quarter earlier.
Fund positioning in DCOY was balanced in Q2 2019: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.
The largest seller was Acadian Asset Management, cutting an estimated $144K.
- 1 institutional investor held Decoy Therapeutics (DCOY) as of Q2 2019, unchanged from Q1 2019.
- Funds reported $1.08M of Decoy Therapeutics stock for Q2 2019, up 8.3% quarter-over-quarter.
- 0 funds opened new Decoy Therapeutics positions in Q2 2019 and 0 closed out.
- The largest Decoy Therapeutics seller in Q2 2019 was Acadian Asset Management, an estimated $144K sold.
Based on aggregated 13F filings for Q2 2019.